Jilin Aodong Pharmaceutical Group , Ltd. EBIT

The latest EBIT for 000623.SZ is $730M as of September 2026. That compares with $18M in the prior-year period — up 3953.2% year over year. That is below the sector sector average of $2.7T. Investors often review this figure alongside Jilin Aodong Pharmaceutical Group , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 000623.SZ's EBIT moved from $18M to $730M — a 3953.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Jilin Aodong Pharmaceutical Group , Ltd.'s operating scale or balance-sheet position.

Against its sector companies, 000623.SZ currently prints $730M for EBIT, while the sector average sits near $2.7T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Jilin Aodong Pharmaceutical Group , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $730M for 000623.SZ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.7T. Explore the charts below for those layers of context.

After noting 000623.SZ's EBIT ($730M), review year-over-year change from $18M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.